Defucosylated Mouse-Dog Chimeric Anti-EGFR Antibody Exerts Antitumor Activities in Mouse Xenograft Models of Canine Tumors.
Animals
Antibodies, Monoclonal
/ pharmacology
Antibody-Dependent Cell Cytotoxicity
Antineoplastic Agents
/ pharmacology
Body Weight
/ drug effects
CHO Cells
Complement System Proteins
/ metabolism
Cricetulus
Dogs
Epidermal Growth Factor
/ pharmacology
ErbB Receptors
/ antagonists & inhibitors
Fucose
/ metabolism
Mice
Recombinant Proteins
/ pharmacology
Tumor Burden
/ drug effects
Xenograft Model Antitumor Assays
ADCC
CDC
EGFR
antitumor activity
canine osteosarcoma
mouse–dog chimeric antibody
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
20 12 2021
20 12 2021
Historique:
received:
03
12
2021
revised:
15
12
2021
accepted:
17
12
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
6
1
2022
Statut:
epublish
Résumé
The epidermal growth factor receptor (EGFR) contributes to tumor malignancy via gene amplification and protein overexpression. Previously, we developed an anti-human EGFR (hEGFR) monoclonal antibody, namely EMab-134, which detects hEGFR and dog EGFR (dEGFR) with high sensitivity and specificity. In this study, we produced a defucosylated mouse-dog chimeric anti-EGFR monoclonal antibody, namely E134Bf. In vitro analysis revealed that E134Bf highly exerted antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity against a canine osteosarcoma cell line (D-17) and a canine fibroblastic cell line (A-72), both of which express endogenous dEGFR. Moreover, in vivo administration of E134Bf significantly suppressed the development of D-17 and A-72 compared with the control dog IgG in mouse xenografts. These results indicate that E134Bf exerts antitumor effects against dEGFR-expressing canine cancers and could be valuable as part of an antibody treatment regimen for dogs.
Identifiants
pubmed: 34944112
pii: cells10123599
doi: 10.3390/cells10123599
pmc: PMC8700185
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antineoplastic Agents
0
Recombinant Proteins
0
Fucose
28RYY2IV3F
Epidermal Growth Factor
62229-50-9
Complement System Proteins
9007-36-7
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Agency for Medical Research and Development
ID : JP21am0401013
Organisme : Japan Agency for Medical Research and Development
ID : JP21am0101078
Organisme : Japan Society for the Promotion of Science
ID : 21K07168
Organisme : Japan Society for the Promotion of Science
ID : 19K07705
Références
Monoclon Antib Immunodiagn Immunother. 2021 Aug;40(4):184-190
pubmed: 34424760
Vet Res Commun. 2019 May;43(2):123-129
pubmed: 31020460
Oncol Rep. 2021 Jul;46(1):
pubmed: 34013368
Cancers (Basel). 2017 May 17;9(5):
pubmed: 28513565
Oncol Lett. 2020 Dec;20(6):383
pubmed: 33154781
Sci Rep. 2020 Jul 10;10(1):11476
pubmed: 32651429
Oncotarget. 2018 Apr 27;9(32):22480-22497
pubmed: 29854293
Ann Oncol. 2005 Feb;16(2):189-94
pubmed: 15668269
Int J Mol Sci. 2020 Aug 21;21(17):
pubmed: 32839411
PLoS One. 2016 Jun 08;11(6):e0157176
pubmed: 27276060
Acta Vet Scand. 2017 Oct 24;59(1):71
pubmed: 29065898
Mol Immunol. 2012 Apr;50(4):200-9
pubmed: 22424313
Exp Ther Med. 2020 Aug;20(2):846-853
pubmed: 32765652
BMC Vet Res. 2016 Jun 04;12:85
pubmed: 27259510
J Gen Virol. 1974 Oct;25(1):21-9
pubmed: 4372315
J Vet Intern Med. 2014 Mar-Apr;28(2):554-63
pubmed: 24512451
J Thorac Dis. 2010 Mar;2(1):48-51
pubmed: 22263017
J Proteomics. 2018 Apr 15;177:124-136
pubmed: 29337282
Oncol Lett. 2017 Jul;14(1):512-516
pubmed: 28693199
Monoclon Antib Immunodiagn Immunother. 2017 Dec;36(6):272-281
pubmed: 29090976
Oncol Rep. 2021 Aug;46(2):
pubmed: 34184091
BMC Vet Res. 2016 May 31;12:82
pubmed: 27245053
Vet J. 2012 Aug;193(2):412-9
pubmed: 22436430
Res Vet Sci. 2006 Dec;81(3):350-7
pubmed: 16556453
Vet Res Commun. 2015 Mar;39(1):61-7
pubmed: 25422073
Vet Pathol. 2017 May;54(3):405-412
pubmed: 28438108
Oncol Rep. 2020 Nov;44(5):1949-1960
pubmed: 33000243
J Am Vet Med Assoc. 1995 May 15;206(10):1555-60
pubmed: 7775232
Cold Spring Harb Perspect Biol. 2014 Apr 01;6(4):a020768
pubmed: 24691965
Vet Clin North Am Small Anim Pract. 1996 Jan;26(1):111-21
pubmed: 8825570
Monoclon Antib Immunodiagn Immunother. 2020 Oct;39(5):167-174
pubmed: 33085938
Ther Deliv. 2011 Mar;2(3):333-44
pubmed: 22834004
Vet Comp Oncol. 2014 Sep;12(3):237-48
pubmed: 22994149
J Am Anim Hosp Assoc. 2009 Jan-Feb;45(1):33-8
pubmed: 19122062
Monoclon Antib Immunodiagn Immunother. 2021 Aug;40(4):177-183
pubmed: 34424762
Oncol Rep. 2020 Dec;44(6):2517-2526
pubmed: 33125138
BMC Vet Res. 2015 Feb 07;11:22
pubmed: 25890299
Scand J Clin Lab Invest. 2019 Dec;79(8):601-612
pubmed: 31663373
Biochem Biophys Rep. 2020 Oct 10;24:100826
pubmed: 33088928
J Am Vet Med Assoc. 2006 Jun 15;228(12):1905-8
pubmed: 16784383
Canine Genet Epidemiol. 2018 Oct 17;5:10
pubmed: 30349728
J Am Vet Med Assoc. 2011 Jan 15;238(2):195-206
pubmed: 21235373
Oncotarget. 2016 Mar 29;7(13):16070-89
pubmed: 26893367
Int J Mol Med. 2020 Oct;46(4):1443-1452
pubmed: 32945346
Mol Cancer Ther. 2014 Jul;13(7):1777-1790
pubmed: 24755200
Vet J. 2018 Nov;241:1-7
pubmed: 30340654
Cancer Treat Rev. 2018 Jan;62:1-8
pubmed: 29126017
Oncol Lett. 2018 Aug;16(2):2185-2194
pubmed: 30008917
Hum Pathol. 2007 Aug;38(8):1184-91
pubmed: 17509661
Cancer. 1993 Apr 15;71(8):2484-90
pubmed: 8453572
J Small Anim Pract. 2010 Oct;51(10):512-24
pubmed: 21029096
Bioengineered. 2013 Mar-Apr;4(2):84-9
pubmed: 23093804
Clin Cancer Res. 2007 May 15;13(10):2998-3005
pubmed: 17505002
Am J Vet Res. 1980 Jun;41(6):855-60
pubmed: 6254399
Vet Pathol. 2005 Jul;42(4):468-76
pubmed: 16006606
Cells. 2020 Nov 23;9(11):
pubmed: 33238582
J Cell Physiol. 2018 Sep;233(9):7457-7466
pubmed: 29663365
Monoclon Antib Immunodiagn Immunother. 2020 Apr;39(2):37-44
pubmed: 32182186
Oncol Lett. 2020 Apr;19(4):2809-2816
pubmed: 32218834